Skip to content

Autoimmune Basis for Postural Tachycardia Syndrome

Autoimmune Basis for Postural Tachycardia Syndrome

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05043051
Enrollment
80
Registered
2021-09-13
Start date
2022-01-14
Completion date
2026-07-31
Last updated
2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postural Tachycardia Syndrome

Keywords

POTS, Vagal Stimulation, Autoantibody

Brief summary

The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.

Detailed description

The present study is designed to test the hypothesis that muscarinic autoantibody-mediated parasympathetic dysfunction contributes to the pathogenesis of POTS, and that parasympathetic (vagal) stimulation improves POTS symptoms, autoimmunity and inflammation. Define and determine the prevalence, burden, and clinical significance of muscarinic autoantibodies in a well-phenotyped cohort of POTS patients with and without gastroparesis and a matched cohort of healthy control subjects. Evaluate the impact of vagal stimulation on antibody suppression, inflammatory inhibition, and symptom improvement in POTS patients. Non-invasive transcutaneous stimulation of the auricular branch of the vagus nerve (tragus stimulation) will be used to increase parasympathetic activity.

Interventions

Vagal stimulation

DEVICESham stimulation

Sham vagal stimulation

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-80 years old, female or male * Either healthy control or individual with postural tachycardia syndrome (POTS) defined as heart rate increase \>30 bpm from supine within 10 min of standing, in the absence of orthostatic hypotension (\>20/10 mmHg fall in blood pressure), with chronic symptoms (\>6 months), and in the absence of other acute cause of orthostatic tachycardia * Able and willing to provide informed consent * Understand and be able to comply with the study procedures and restrictions

Exclusion criteria

* Hypertension (\>150 mmHg systolic and \>100 mmHg diastolic) based on history or findings at screening * Orthostatic hypotension (consistent drop in blood pressure \>20/10 mmHg with 10 min of standing) * Cardiovascular disease, such as myocardial infarction within 6 months * History or presence of significant immunological or hematological disorders * History of vagotomy * Currently pregnant women or women planning on becoming pregnant ≤ 3 months * Inability to comply with the protocol * Patients with active implants (such as a cardiac pacemaker, or a cochlear implant) Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender.

Design outcomes

Primary

MeasureTime frameDescription
Heart rate variability5 minuteAverage of heart rate variability during the posture test

Countries

United States

Contacts

Primary ContactXichun Yu
xichun-yu@ouhsc.edu405-271-5896
Backup ContactBrittany Karfonta
Brittany-Karfonta@ouhsc.edu405-271-3480

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026